Oncology
Tissue-Agnostic Medicine Has a New Proof Point
The FDA has converted selpercatinib to traditional approval for RET fusion-positive solid tumours in adults and children. The decision strengthens tissue-agnostic precision oncology, but testing gaps still decide who is found.
Cancer Is Chaos. Patients Should Not Have to Become Their Own Operating System
Surviving Cancer Is Not the Same as Being Recovered
CAR-T Starts Moving From Factory Medicine to In-Patient Engineering
AML’s Frontline Future Starts With Finding the Mutation Fast
GIST Care Looks Beyond First-Generation KIT Control
Pancreatic Cancer Finally Gets a RAS Moment
GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race
J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race
Cancer Sequencing Becomes the Operating System of Precision Oncology
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.